Transition metal complexes are considered a significant treatment for cancer diseases because of their efficacy toward cancer cells. However, most of these compounds have limited potential toward cancer cells due to their organic backbone structure. Here, the synthesis and anticancer screening of three different ligand structures of salen copper(II) complexes are reported: [Cu II (salophen)(H 2 O) 2 ] ( 1 ), [Cu II (salen)(H 2 O) 2 ] ( 2 ), and [Cu II (etho‐salen)(H 2 O) 2 ] ( 3 ). Using density functional theory‐optimized structures, docking active site interactions are evaluated to predict the activity of salen‐type ligands and their copper(II) complexes against cyclin‐dependent kinase 5 (Cdk5 ) and aromatase cytochrome (P450) proteins. The molecular docking study reveals that among all studied ligands and complexes, [Cu II (salen)(H 2 O) 2 ] ( 2 ) has the best docking score value, S = −8.79 and −7.73, with the lowest root mean square deviation (RMSD = 1.02 and 1.09) against proteins Cdk5 and P450, respectively. Anticancer activity against MCF‐7 and HCT‐116 cell lines reveals that [Cu II (salen)(H 2 O) 2 ] ( 2 ) shows favorable behavior with IC 50 values of 212.5 and 98.9 μ m , respectively. Its parent ligand 2 shows lower potency, with IC 50 values of 404.7 μ m in MCF‐7 and 305.2 μ m in HCT‐116. Notably, copper(II) complexes display reduced toxicity rather than cisplatin toward normal HFF‐1 fibroblasts, indicating a more favorable therapeutic window.
1
11 September 2025 in International Journal of Biological Macromolecules
Novel 2-aminomethyl benzimidazole (AMBI) ruthenium complexes were synthesized and thoroughly characterized by elemental analysis, spectroscopy (FTIR, 1HNMR, UV–Vis), magnetic measurements, molar conductivity, and thermal analysis techniques. According to analytical data, all complexes demonstrated a 1:1 metal-to-ligand ratio with an octahedral shape. Thermal analysis showed that the complexes have acceptable thermal stability. Cyclic voltammetry was also used to observe their redox actions, and it was found that all of the complexes had electrochemical activity. Using GAUSSIAN 09 W software, the density functional theory (DFT) method and the 3-21G basis set, optimized structures (HOMO & LUMO) of ruthenium complexes (1-4) were carried out. Additionally, the selected quantum and geometric parameters of bond lengths and angles have been determined. The antimicrobial activity of ligand and ruthenium complexes has been evaluated against bacteria (Escherichia coli, Staphylococcus aureus) and fungi (Candida albicans). Two human cancers, HePG-2(hepatocellular carcinoma) and MCF-7 (Michigan Cancer Foundation-7), were tested for cytotoxic activity of complexes. Using the ABTS technique, the antioxidant function of complexes was evaluated. Using a high-affinity Fab sandwich and a specific PCa antibody, molecular docking was utilized to anticipate how the ligand would bind to a human prostate-specific antigen (PSA) immune system receptor (3qum).